Regulation of adipogenesis by medium-chain fatty acids in the absence of hormonal cocktail.
We report here that octanoate and decanoate, 8-carbon and 10-carbon medium-chain fatty acids (MCFA), decreased adipogenesis in 3T3-L1 preadipocytes when treated with standard hormonal cocktail, but increased adipogenesis in a dose-dependent manner (with decanoate being more effective) when treated with basal media. Addition of dexamethasone to basal medium with either octanoate or decanoate further increased adipogenesis. In order to understand the adipogenic effects of MCFA in the absence of standard hormonal cocktail, postconfluent 3T3-L1 preadipocytes were treated with octanoate or decanoate, and the change in the expression of several adipogenic transcription factors and enzymes was investigated using real-time RT-PCR. Octanoate and decanoate up-regulated the mRNA expression of peroxisome-proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, fatty-acid-binding protein, sterol-regulatory element binding protein 1c, lipoprotein lipase and hormone-sensitive lipase, and the protein expression of PPARgamma and C/EBPalpha, with decanoate being more effective. Moreover, the PPARgamma antagonist GW9662 inhibited MCFA-induced lipid accumulation by about 50%. Decanoate and octanoate, to a lesser degree, increased lipid accumulation, which was associated with an increase in glycerol-3-phosphate dehydrogenase activity. These results show that octanoate and decanoate may stimulate differentiation of preadipocytes, at least in part, by their influence on the expression of PPARgamma and other adipocyte-specific factors.
Yang
Jeong-Yeh
JY
Department of Animal and Dairy Science, University of Georgia, Athens, GA 30602-2771, USA.
Della-Fera
Mary Anne
MA
Rayalam
Srujana
S
Park
Hea Jin
HJ
Ambati
Suresh
S
Hausman
Dorothy B
DB
Hartzell
Diane L
DL
Baile
Clifton A
CA
D041721:3T3-L1 Cells; D017667:Adipocytes / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D050156:Adipogenesis / Q000187:drug effects*; D000813:Anilides / Q000494:pharmacology; D000818:Animals; D000840:Anisoles / Q000494:pharmacology; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000378:metabolism; D002210:Caprylates / Q000494:pharmacology*; D003651:Decanoates / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D005993:Glycerolphosphate Dehydrogenase / Q000235:genetics / Q000378:metabolism; D006728:Hormones / Q000494:pharmacology; D050356:Lipid Metabolism; D051379:Mice; D047495:PPAR gamma / Q000037:antagonists & inhibitors; D014157:Transcription Factors / Q000378:metabolism
C457499:2-chloro-5-nitrobenzanilide; D000813:Anilides; D000840:Anisoles; D022763:CCAAT-Enhancer-Binding Protein-alpha; D002210:Caprylates; D003651:Decanoates; D006728:Hormones; D047495:PPAR gamma; D014157:Transcription Factors; C031050:isomethyleugenol; D003907:Dexamethasone; D005993:Glycerolphosphate Dehydrogenase; C031492:octanoic acid